U.S. Markets closed

Johnson & Johnson Earnings: When Strong Isn't Strong Enough

Not much has changed for the health-care conglomerate, analysts said, but there was enough for investors to take some profits. “In this market, a company—not just J&J—needs to deliver clean, perfect quarterly results and guides, not just on the headline number but everything that goes into it,” Glenn Novarro, an analyst at RBC Capital Markets, tells Barron’s. He still has an outperform rating on the stock.